Nature Communications

TG4050 TG4050 as a single agent has the potential to prevent recurrence in head and neck cancer   Peer-reviewed publication in Nature Communications highlights the Phase 1 clinical and translational findings   Article available for the first time on Nature Communications website – Download the Article

Advancing our pipeline

Expanding myvac® TG4050, Head and neck cancer (adjuvant) – Phase 2 ongoing TG4070, Non-small cell lung cancer (adjuvant) – Phase 1 . Explore Our Pipeline Looking ahead to 2026-2027 * video need cookies analytics